Larimar Therapeutics IncLRMR
Price$3.06

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$172.6MTTM through 30 Jun 2026
Free Cash Flow -$156.1MTTM through 30 Jun 2026

Margins

Current

Returns

-18.7%ROE
-14.2%ROA

Balance Sheet Health

Debt / Equity0.02x
Current Ratio4.29x
Net Debt-$196.6Mnet cash position
Cash & Equivalents$92.7M

Quality Metrics

Altman Z-Score-0.59
Piotroski F-Score2 / 9
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'13'14'15'16'17'18'19
FY2019: $0
Diluted EPS-$1.96TTM
'20'21'22'23'24
FY2024: $-1.32

Dividend

No dividend

Capital Allocation

R&D Spend$157.3M

Segment Performance

SegmentRevenueYoYOutlook
Nomlabofusp Development$0
View details

Targeting potential U.S. launch in the first half of 2027 if approved.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.